Genentech Inc. is partnering with Seattle-based Adaptive Biotechnologies Corp. to develop a new type of cell therapy for solid cancers targeting individual's tumor-specific proteins, or neoantigens. Under terms of the cancer immunotherapy deal, which leverages Adaptive's TruTCR screening platform, Genentech will pay Adaptive $300 million up front as well as potential development, regulatory and commercial milestones valued at more than $2 billion, plus royalties. The deal is expected to close in the first quarter.